Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2004-01-14
2009-02-17
Hayes, Robert C (Department: 1649)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Reexamination Certificate
active
07491799
ABSTRACT:
Natural and modified neurotoxins and isolated neurotoxin compositions are described. The neurotoxins may include one or more structural modifications, wherein the structural modification(s) alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification(s). In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In some embodiments, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular ailments and pain.
REFERENCES:
patent: 4932936 (1990-06-01), Dykstra et al.
patent: 5053005 (1991-10-01), Borodic
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5714986 (1998-02-01), Dao
patent: 5721215 (1998-02-01), Aoki et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6143306 (2000-11-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6306423 (2001-10-01), Donovan
patent: 6312708 (2001-11-01), Donovan
patent: 6328977 (2001-12-01), Donovan
patent: 6358513 (2002-03-01), Voet et al.
patent: 6365164 (2002-04-01), Schmidt
patent: 6395277 (2002-05-01), Graham
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 2003/0027752 (2003-02-01), Steward et al.
patent: 2003/0219462 (2003-11-01), Steward et al.
patent: WO94/15629 (1994-07-01), None
patent: WO 96/39166 (1996-12-01), None
patent: WO 97/32599 (1997-09-01), None
patent: WO 00/05252 (2000-02-01), None
patent: WO 02/08268 (2002-01-01), None
Rudinger, In “Peptide Hormones” (ed. J.A. Parsons), University Park Press, Baltimore, pp. 1-7 (1976).
Adenis, et al., J. Fr. Ophthamol. (1990) 13:259-264. (Abstract only in English).
Binz, et al., J. Biol. Chem. (1990) 265:9153-9158.
Blitzer, et al., Ann. Otol. Rhinol Laryngol. (1985) 94:591-594.
Brin, et al., Advances in Neurology, vol. 50: Dystonia 2 (1988), pp. 599-608.
Di Bello, et al., Eur. J. Biochem. (1994) 219:161-169.
Cohn, et al., Neurology (1987) 37 (3 Supp. 1):123-124. (abstract only).
Elston, et al., Br. J. Opthamol. (1985) 69:718-724.
Elston, et al., Br. J. Opthamol. (1985) 69:891-896.
Galli, et al., Cell (1998) 9:1437-1448.
Jancovic, et al., Neurology (1987) 37:616-623.
Li, et al., Biochemistry (1994) 33:7014-7020.
Maisey, et al., Eur. J. Biochem. (1988) 177:683-691.
Martinez-Arca, et al., J. Cell Biol. (2000) 149:889-899.
Milton, et al., Biochemistry (1992) 31:8799-8809.
Minton, In Clostridial Neurotoxins: the molecular pathogenesis of tetanus and botullsm,Montecucco, ed., Springer Verlag, NY, 1995, pp. 161-194.
Swain, et al., Peptide Res. (1993) 6:147-154.
Zhou, et al., Biochemistry (1995) 34:15175-15181.
Shin, et al., J. Biol. Chem. (1991) 266:10658-10665.
Rasiborska and Charlton, Can. J. Physiol. (1999) 77:679-688.
Erdal, et al., Arch. Pharmacol. (1995) 351:67-78.
Ragona, et al., The Larangyscope (1999) 109:1344-1346.
Naumann, et al., Eur. J. Neurol. (1999) 6:S111-S115.
Keller, et al., FEBS Lett. (1999) 456:137-142.
Dietrich, et al., J. Cell. Biol. (1997) 138:271-281.
Geisler, et al., J. Biol. Chem. (1998) 273:21316-21323.
Tan, et al., J. Biol. Chem. (1998) 273:17351-17360.
Liu, et al., Trends Cell Biol. (1999) 9:356-363.
Cai and Singh, Biochemistry (2001) 40:4693.
Tikkanen, et al., Traffic (2000) 1:631-640.
Rapaport, et al., EMBO J. (1998) 17:2148-2155.
Miranda, et al., JBC Papers in Press (2001) 1-35.
Cowles, et al., Cell (1997) 91:109-118.
Aoki, et al., J. Neurol. (2001) 248 (Supp 1):3-10.
Aoki, Toxicon, (2001) 12:1815-1820.
Wiegand, et al., Nauny Schmiedberg's Arch. Pharmacol. (1976) 292.
Haberman, Nauny Schmiedberg's Arch. Pharmacol. (1974) 281.
Thompson, et al., Eur. J. Biochem. (1990) 189:73.
Arnon, et al., “Botulinum toxin as a biological weapon: medical and public health management,” JAMA (2001) 285:1059-1070.
Eswaramoorthy, et al., “A novel mechanism for Clostridium botulinum neurotoxin inhibition,” Biochemistry (2002) 41:9795-9802.
Aoki, et al., “Is the light chain subcellular localization an important factor for botulinum neurotoxin duration of action?,” Naunyn Schmiedebergs Arch. Pharmacol. (2002) 385 (Suppl 2):R10.
Fernandez-Salas, et al., “Localization of BoNT light chains in neuronal and non-neuronal cell lines, implications for the duration of action of the different serotypes,” Naunyn Schmiedebergs Arch. Pharmacol. (2002) 365 (Suppl 2):R19.
Steward, et al., “BoNT/A light chain and the dileucine motif: potential implications for light chain localization and neurotoxin duration of action,” Naunyn Schmiedebergs Arch. Pharmacol. (2002) 385 (Suppl 2):R44.
Fernandez-Salas, et al., “Plasma Membrane Localization Signals in the Light Chain of Botulinum Neurotoxin,” Slide presentation at USAMROD, Jan. 2004.
Fernandez-Salas, et al., “Plasma membrane localization signals in the light chain of botulinum neurotoxin,” Proc. Natl. Acad. Sci. USA (2004) 101:3208-3213.
Fernandez-Salas, et al., “Is the light chain subcellular localization an important factor in Botulinum toxin duration of action?” Movement Disorders (2004) 19:S23-S34.
Fernandez-Salas, E., et al.,Plasma membrane localization signals in the light chain of botulinum neurotoxin serotype A, Society of Neuroscience Abstract Viewer and Itinerary Planner, vol. 2003; pp. Abstract No. 9.2.
Foran, Patrick G., et al.,Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons, Journal of Biological Chemistry, vol. 278, No. 2, Jan. 10, 2003, pp. 1363-1371.
Wang Xingmin, et al.,Genetic analysis of type E botulinum toxin-producing Clostridium butyricum strains, Applied and Environmental Microbiology, vol. 66, No. 11, Nov. 2000, pp. 4992-4997.
Fernandez-Salas, E., et al.,Plasma membrane localization signals in the light chain of botulinum neurotoxin, Proceedings of the National Academy of Sciences of the United States of America, Mar. 2, 2004, vol. 101, No. 9, pp. 3208-3213.
Zhou et al., “Expression and purification of the light chain of botulinum neurotoxin A: A single mutation abolishes its cleavage of SNAP-25 and neurotoxicity after reconstruction with the heavy chain”, Biochemistry, vol. 34, No. 46, pp. 15175-15181, 1995.
Darsow et al, J. Cell Biol. (1998) 142-913-922.
Fauci et al, Harrison's Principles of Internal Medicine 14thEdition, (1998), McGaw Hill- (table of contents only).
Kadhodayan et al, Protein Express (2000) 19: 125-130.
Kozaki et al, J. Med. Sci Biol. (1981) 34:61-68.
Lacy et al, Biochemistry (1994) 33: 7014-7020.
Peden et al, J. Biol. Chem. (2001) 276-49183-49187.
Press Release, “Protein Turnover and Autophagy”, American Society for Cell Biology, Jan. 1, 1990.
Aoki Kei Roger
Fernandez-Salas Ester
Herrington Todd M.
Steward Lance E.
Allergan Inc.
German Joel B.
Hayes Robert C
Stathakis Dean G.
Voet Martin A.
LandOfFree
Modified botulinum neurotoxins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified botulinum neurotoxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified botulinum neurotoxins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4060328